Nachega 2020.

Study characteristics
Notes	English title Clinical characteristics and outcomes of patients hospitalized for COVID‐19 in Africa: early insights from the Democratic Republic of the Congo  Study setting Start of study recruitment (MM/YYYY): 03/2020 End of study recruitment (MM/YYYY): 07/2020 Study design: Retrospective cohort Study centre(s): Multiple centres/clinics/areas within a country Number of centres/clinics/areas: 7 Study setting: Inpatient Number of participants recruited: 766 Sampling method: Consecutive participants Participants Female participants (absolute number): 262 Age measure, value: Median (IQR), 46 (34‐58) Inclusion criteria: All COVID‐19 patients admitted at the seven largest health facilities in Kinshasa (one private, two faith‐based Catholic, and four public) Exclusion criteria: NR Smoking frequency: NR Diabetes frequency: 107 Hypertension frequency: 194 Cardiovascular disease frequency: 30 Asthma frequency: NR Chronic obstructive pulmonary disease frequency: NR Other pulmonary disease frequency: NR Immunosuppression frequency: NR Chronic kidney disease frequency: 7 Cancer frequency: 5 Steroid administration frequency: NR Supplemental oxygen administration frequency: NR Other treatments (absolute number): Chloroquine (630), azithromycin (742) Prognostic factor(s) Study’s definition for obesity: NR The time when obesity has been measured: Before disease or right at presentation Main variable used for determination of obesity: NR Threshold used for definition of obesity: NR Obesity frequency (absolute number): 39 Prognostic factor(s): Obesity Outcome(s) Mortality Outcome (prognostic factor) Mortality (obesity) Follow‐up Number of patients followed completely for the outcome: 764 Number of obese patients followed completely for the outcome: 39 Number of non‐obese patients followed completely for the outcome: 725 Univariable unadjusted analysis for obesity Effect measure for obesity: Hazard ratio Effect measure value (95% CI), P value: 3.87 (2.86, 6.56), NR Multivariable analysis for obesity Modelling method: Cox regression The set of prognostic factors used for adjustment: Age, hypertension, diabetes mellitus, heart disease, chronic kidney disease (CKD), cancer, chloroquine/azithromycin‐based treatment vs. other Effect measure for obesity: Hazard ratio Effect measure value (95% CI), P value: 2.3 (1.24, 4.27), 0.009
Item	Authors' judgement	Support for judgement
Study Participation	Yes	Appendix 3
Study Attrition Mortality	Yes	Appendix 3
Prognostic Factor Measurement	No	Appendix 3
Outcome Measurement Mortality	Yes	Appendix 3
Confounding Bias Mortality	Yes	Appendix 3
Statistical Analysis Bias	Yes	Appendix 3